摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-bromo-2,3-dihydro-7-methoxybenzofuran-2-spiro-1'-cyclopentane | 185244-55-7

中文名称
——
中文别名
——
英文名称
4-bromo-2,3-dihydro-7-methoxybenzofuran-2-spiro-1'-cyclopentane
英文别名
4-Bromo-7-methoxy-spiro[2,3-dihydrobenzofuran-2,1'-cyclopentane];4-bromo-7-methoxy-spiro[benzofuran-2,1'-cyclopentane];4-Bromo-7-methoxy-3h-spiro[benzofuran-2,1'-cyclopentane];4-bromo-7-methoxyspiro[3H-1-benzofuran-2,1'-cyclopentane]
4-bromo-2,3-dihydro-7-methoxybenzofuran-2-spiro-1'-cyclopentane化学式
CAS
185244-55-7
化学式
C13H15BrO2
mdl
——
分子量
283.165
InChiKey
DBUZWESZMNGRDG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    365.6±42.0 °C(Predicted)
  • 密度:
    1.47±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-bromo-2,3-dihydro-7-methoxybenzofuran-2-spiro-1'-cyclopentane正丁基锂 、 sodium hydride 、 一水合肼 作用下, 以 四氢呋喃乙醇正己烷N,N-二甲基甲酰胺 为溶剂, 反应 13.25h, 生成 cis-2-benzyl-4-{spiro[cyclopentane-1',2(3H)-7-methoxybenzofurane]-4-yl}-4a,5,6,7,8,8a-hexahydro-2H-phthalazin-1-one
    参考文献:
    名称:
    Novel Selective PDE4 Inhibitors. 2. Synthesis and Structure−Activity Relationships of 4-Aryl-Substituted cis-Tetra- and cis-Hexahydrophthalazinones
    摘要:
    A series of 4-aryl-substituted cis-4a,5,8,8a-tetra- and cis-4a,5,6,7,8,8a-hexahydro-2H-phthalazin-1-ones with high inhibitory activity toward cAMP-specific phosphodiesterase (PDE4) was synthesized. To study structure-activity relationships various substituents were introduced to the 2-, 3-, and 4-positions of the 4-phenyl ring. Substitution at the 4-position of the phenyl ring was restricted to a methoxy group, probably due to unfavorable steric interactions of larger groups with the binding site. The introduction of many alkoxy substituents including distinct ring systems and functional groups was allowed to the 3-position. It was found that in general the cis-4a,5,8,8a-tetrahydro-2H-phthalazin-1-ones are more potent than their hexahydrophthalic counterparts, the best activity residing in (4-imidazol-1-yl-phenoxy)butoxy analogue 16o (pIC(50) = 9.7).
    DOI:
    10.1021/jm010838c
  • 作为产物:
    参考文献:
    名称:
    [EN] BORATE DERIVATIVE AND USES THEREOF
    [FR] DÉRIVÉ DE BORATE ET SES UTILISATIONS
    [ZH] 一种硼酸酯衍生物及其用途
    摘要:
    提供一种如式I所示化合物或其可药用盐,以及所述化合物在制备预防和/或治疗与PDE相关病症的药物中的应用。
    公开号:
    WO2022135550A1
点击查看最新优质反应信息

文献信息

  • DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE
    申请人:——
    公开号:US20020128290A1
    公开(公告)日:2002-09-12
    An oxygen-containing heterocyclic compound represented by following Formula (I): 1 wherein R 1 and R 2 independently represent hydrogen, lower alkyl, cyano, —(CH 2 ) n —E 1 —CO—G 1 (wherein E 1 represents a bond, O, or NH; and G 1 represents hydrogen, substituted or unsubstituted lower alkyl, OR 6 , or NR 7 R 8 ; and n represents an integer of 0 to 4), or the like; R 1 and R 2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R 2 , and R 11 or R 13 described below are combined to form a single bond; R 3 represents hydrogen, phenyl, or halogen; R 4 represents hydroxy, lower alkoxy, or the like; A represents —C(R 9 )(R 10 )— or O; B represents O, NR 11 , —C(R 12 )(R 13 )—, or —C(R 14 )(R 15 )—C(R 16 )(R 17 )—; D represents (i) —C(R 18 )(R 19 )—X— (wherein X represents —C(R 21 )(R 22 )—, S, or NR 23 ), (ii) —C(R 19a )═Y— [Y represents —C(R 24 )—Z— (wherein Z represents CONH, CONHCH 2 , or a bond), or N], or (iii) a bond; and R 5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or pharmaceutically acceptable salts thereof.
    以下是由下式(I)表示的含氧杂环化合物: 其中R1和R2独立地表示氢、较低的烷基、氰基、—(CH2)n—E1—CO—G1(其中E1表示键、O或NH;G1表示氢、取代或未取代的较低烷基、OR6或NR7R8;n表示0到4的整数),或类似物;R1和R2结合表示与相邻碳原子一起形成饱和碳环;或R2,以及下文描述的R11或R13结合形成单键;R3表示氢、苯基或卤素;R4表示羟基、较低的烷氧基或类似物;A表示—C(R9)(R10)—或O;B表示O、NR11、—C(R12)(R13)—或—C(R14)(R15)—C(R16)(R17)—;D表示(i)—C(R18)(R19)—X—(其中X表示—C(R21)(R22)—、S或NR23)、(ii)—C(R19a)═Y—[Y表示—C(R24)—Z—(其中Z表示CONH、CONHCH2或键),或N],或(iii)键;R5表示芳基、芳香杂环基、环烷基、吡啶-N-氧化物、氰基或较低烷氧羰基;或其药学上可接受的盐。
  • Therapeutic Piperazines
    申请人:Keenan P. Terrence
    公开号:US20070203124A1
    公开(公告)日:2007-08-30
    The invention includes a compound of formula I: wherein R 1 , X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in animals.
    该发明包括式I的化合物: 其中R 1 ,X,Z,n和m具有本文所述的任何值,以及这些化合物的盐,包含这些化合物的组合物,以及包括给予这些化合物的治疗方法。这些化合物是PDE4功能的抑制剂,对于改善动物的认知功能是有用的。
  • Pyrrolopyridazinone Compound
    申请人:Hagihara Masahiko
    公开号:US20090036453A1
    公开(公告)日:2009-02-05
    The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group —O—R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), “C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group”, an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or “C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group”, Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl)C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.
    本发明公开了一种由式(1)表示的吡咯吡啶二酮化合物:其中,R1代表C1-C2烷基或卤代C1-C2烷基,R2代表C3-C5环烷基、(C3-C5环烷基)C1-C2烷基或C1-C3烷基,R3代表氢原子,或与基团-O-R2结合形成取代含氧杂环的亚甲基或顺式乙烯基,R4代表氢原子、卤素原子、C1-C8烷基、C2-C6烯基、C2-C6炔基、羟基C3-C6烯基、羟基C3-C6炔基、由从取代基团(a)中选择的取代基团取代的C1-C6烷基,可由从取代基团(b)中选择的取代基团取代的C3-C6环烷基,可由从取代基团(b)中选择的取代基团取代的C1-C3烷基,且可由羟基取代,芳香环基或杂芳香环基,每个都可由从取代基团(c)中选择的取代基团取代或由取代基团(c)选择的基团取代的C1-C2烷基,且可由羟基取代,取代基团(a)表示卤素原子、羟基、氰基、羧基、C1-C5烷氧基、卤代C1-C4烷氧基、C3-C6环烷氧基、(C3-C6环烷基)C1-C2烷氧基、C1-C4烷氧羰基、C2-C4酰基、C2-C4酰氧基或C1-C4烷基取代的氨基基团,取代基团(b)表示羟基或卤素原子,取代基团(c)表示卤素原子、羟基、氰基、硝基、羧基、C1-C5烷氧基、C1-C4烷氧羰基、C2-C4酰氧基、C1-C4烷基取代的氨基基团或可由从由卤素原子、羟基和羧基组成的基团中选择的取代基团取代的C1-C4烷基,或其药学上可接受的盐。
  • THERAPEUTIC PIPERAZINES
    申请人:Keenan Terence P.
    公开号:US20110065689A1
    公开(公告)日:2011-03-17
    The invention includes a compound of formula I: wherein R 1 , X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in animals.
    该发明包括式I的化合物:其中R1、X、Z、n和m具有本文所述的任何值,以及这些化合物的盐、包含这些化合物的组合物以及包括这些化合物的治疗方法。这些化合物是PDE4功能抑制剂,对于改善动物的认知功能有用。
  • PIPERAZINE PDE4 INHIBITORS AND USES THEREOF
    申请人:DART NEUROSCIENCE (CAYMAN) LTD
    公开号:US20140038945A1
    公开(公告)日:2014-02-06
    The invention includes a compound of formula I: wherein R 1 , X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds ate inhibitors of PDE 4 function and are useful for improving cognitive function in animals.
    该发明涉及一种化合物,其化学式为I:其中R1、X、Z、n和m可以取本文所述的任何值,以及该化合物的盐、包含该化合物的组合物和包括该化合物的治疗方法。该化合物是PDE4功能抑制剂,对于改善动物的认知功能是有用的。
查看更多

同类化合物

顺式-1-((2-(5-氯-2-苯并呋喃基)-4-甲基-1,3-二氧戊环-2-基)甲基)-1H-1,2,4-三唑 顺式-1-((2-(5,7-二氯-2-苯并呋喃基)-4-乙基-1,3-二氧戊环-2-基)甲基)-1H-咪唑 顺式-1-((2-(2-苯并呋喃基)-4-乙基-1,3-二氧戊环-2-基)甲基)-1H-1,2,4-三唑 霉酚酸酯杂质B 间甲酚紫 间甲基苯基(苯并呋喃-2-基)甲醇 长管假茉莉素C 金霉素 酪氨酸,b-羰基- 酞酸酐-d4 酚酞二丁酸酯 酚酞 酚红钠 酚红 邻苯二甲酸酐与马来酸酐,甘氨酰蜡素和二乙二醇的聚合物 邻苯二甲酸酐与己二醇的聚合物 邻苯二甲酸酐与三甘醇异壬醇的聚合物 邻苯二甲酸酐与2-乙基-2-羟甲基-1,3-丙二醇和2,5-呋喃二酮的聚合物 邻苯二甲酸酐与2-乙基-2-羟甲基-1,3-丙二醇、2,5-呋喃二酮和2-乙基己酸苯甲酸酯的聚合物 邻苯二甲酸酐-4-硼酸频哪醇酯 邻苯二甲酸酐,马来酸,二乙二醇,新戊二醇聚合物 邻甲酚酞 贝康唑 表灰黄霉素 螺佐呋酮 螺[苯并呋喃-3(2H),4-哌啶] 螺[异苯并呋喃-1(3H),4’-哌啶]-3-酮 螺[异苯并呋喃-1(3H),4'-哌啶]-3-酮盐酸盐 螺[异苯并呋喃-1(3H),3’-吡咯烷]-3-酮 螺[1-苯并呋喃-2,1'-环丙烷]-3-酮 薄荷内酯 莫罗卡尼 荨麻叶泽兰酮 荧光胺 苯酞-3-乙酸 苯酐二乙二醇共聚物 苯酐 苯甲酸,2-[(1,3-二羰基丁基)氨基]-,甲基酯 苯甲酸,2,2-二(羟甲基)丙烷-1,3-二醇,异苯并呋喃-1,3-二酮 苯甲酰氯化,3-甲氧基-4-甲基- 苯甲基(1-{(2-amino-2-methylpropanoyl)[(2S)-2-aminopropanoyl]amino}-2-methyl-1-oxopropan-2-yl)甲基氨基甲酸酯(non-preferredname) 苯并呋喃并[3,2-d]嘧啶-2,4(1H,3H)-二酮 苯并呋喃并[3,2-D]嘧啶-4(1H)-酮 苯并呋喃并[2,3-d]哒嗪-4(3H)-酮 苯并呋喃并(3,2-c)吡啶,1,2,3,4-四氢-2-(2-(二甲氨基)乙基)-,二盐酸 苯并呋喃与1H-茚的聚合物 苯并呋喃[3,2-b]吡咯-2-羧酸 苯并呋喃-7-羧酸 苯并呋喃-7-硼酸频那醇酯 苯并呋喃-7-甲腈